[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100225171":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":22,"locations":31,"responsibleParty":173,"collaborators":176,"id":184,"slug":185,"hasResults":186,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":186,"sex":192,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":198,"studyType":199,"phases":10,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},{"fullName":5,"class":6},"Russian Cardiology Research and Production Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients diagnosed with FH",null,"Subjects of both sexes above the age of 18 with TC ≥7.5 mmol\u002FL or LDL-C ≥4.9 mmol\u002FL will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.\n\nThose with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c \\>8%) or hypothyroidism (thyroid-stimulating hormone \\>1.5 upper normal limit), renal failure (creatinine clearance \\\u003C30 ml\u002Fmin), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study.",[13,16,19],{"name":14,"affiliation":5,"role":15},"Valery Kukharchuk, MD, DMSc","STUDY_CHAIR",{"name":17,"affiliation":5,"role":18},"Igor Sergienko, MD, DMSc","STUDY_DIRECTOR",{"name":20,"affiliation":5,"role":21},"Marat Ezhov, MD, DMSc","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Marat Ezhov, MD, PhD","CONTACT","+79104137499","Marat_Ezhov@mail.ru",{"name":17,"role":25,"phone":29,"phoneExt":10,"email":30},"+79031492253","igorcardio@mail.ru",[32,61,100,128,150],{"facility":33,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Chelyabinsk State Medical Academy","NOT_YET_RECRUITING","Chelyabinsk","454092","Russia","RU",{"type":40,"coordinates":41},"Point",[42,43],61.42877,55.1611,{"lat":43,"lon":42},[46,50,54,55,57,59],{"name":47,"role":25,"phone":48,"phoneExt":10,"email":49},"Igor Shaposhnik, MD, DMSc","+79088235120","shaposhnik@yandex.ru",{"name":51,"role":25,"phone":52,"phoneExt":10,"email":53},"Bogdanov Dmitriy, MD, PhD","+79124773437","dmitrchel@mail.com.ru",{"name":47,"role":21,"phone":10,"phoneExt":10,"email":10},{"name":51,"role":56,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":58,"role":56,"phone":10,"phoneExt":10,"email":10},"Salashenko Aleksey, MD\u003C PhD",{"name":60,"role":56,"phone":10,"phoneExt":10,"email":10},"Genkel Vadim, MD, PhD",{"facility":62,"status":63,"city":64,"state":10,"zip":65,"country":37,"countryCode":38,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"EI Chazov National Medical Research Center of Cardiology","RECRUITING","Moscow","121552",{"type":40,"coordinates":67},[68,69],37.61781,55.75204,{"lat":69,"lon":68},[72,74,76,78,80,82,84,86,88,90,92,94,96,98],{"name":24,"role":25,"phone":73,"phoneExt":10,"email":27},"+791041374993558",{"name":75,"role":25,"phone":29,"phoneExt":10,"email":30},"Igor Sergienko, MD, PhD",{"name":77,"role":56,"phone":10,"phoneExt":10,"email":10},"Vladmir Malakhov, MD,PhD",{"name":79,"role":56,"phone":10,"phoneExt":10,"email":10},"Diana Nozadze, MD,PhD",{"name":81,"role":56,"phone":10,"phoneExt":10,"email":10},"Natalya Gornyakova, MD,PhD",{"name":83,"role":56,"phone":10,"phoneExt":10,"email":10},"Alexey Ansheles, PhD",{"name":85,"role":56,"phone":10,"phoneExt":10,"email":10},"Tatiana Balakhonova, MD, DMSc",{"name":87,"role":56,"phone":10,"phoneExt":10,"email":10},"Olga Pogorelova, PhD",{"name":89,"role":56,"phone":10,"phoneExt":10,"email":10},"Maria Tripoten, PhD",{"name":91,"role":56,"phone":10,"phoneExt":10,"email":10},"Grigory Heymets, PhD, DSc",{"name":93,"role":56,"phone":10,"phoneExt":10,"email":10},"Narek Tmoyan, MD",{"name":95,"role":56,"phone":10,"phoneExt":10,"email":10},"Ulyana Chubykina, MD",{"name":97,"role":56,"phone":10,"phoneExt":10,"email":10},"Svetlana Bliznyuk, MD",{"name":99,"role":56,"phone":10,"phoneExt":10,"email":10},"Tatyana Rozhkova, MD",{"facility":101,"status":34,"city":102,"state":10,"zip":103,"country":37,"countryCode":38,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Novosibirsk Research Institute of Internal Medicine, Institute of Internal Medicine Siberian Branch of the Russian Academy of Medical Sciences","Novosibirsk","630089",{"type":40,"coordinates":105},[106,107],82.93175,55.02259,{"lat":107,"lon":106},[110,114,118,119,120,122,124,126],{"name":111,"role":25,"phone":112,"phoneExt":10,"email":113},"Mikhail Voevoda, MD, DMSc","+79139505088","mvoevoda@ya.ru",{"name":115,"role":25,"phone":116,"phoneExt":10,"email":117},"Yulia Ragino, MD, DMSc","+79537799704","ragino@mail.ru",{"name":111,"role":21,"phone":10,"phoneExt":10,"email":10},{"name":115,"role":56,"phone":10,"phoneExt":10,"email":10},{"name":121,"role":56,"phone":10,"phoneExt":10,"email":10},"Elena Shakhtshneider, MD, DMSc",{"name":123,"role":56,"phone":10,"phoneExt":10,"email":10},"Ksenia Makarenkova, MD, PhD",{"name":125,"role":56,"phone":10,"phoneExt":10,"email":10},"Elena Antonova, MD, PhD",{"name":127,"role":56,"phone":10,"phoneExt":10,"email":10},"Elena Voevoda, MD",{"facility":129,"status":34,"city":130,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Saint-Petersburg State University and North-West State Medical University n.a. I.I.Mechnikov","Saint Petersburg",{"type":40,"coordinates":132},[133,134],30.31413,59.93863,{"lat":134,"lon":133},[137,141,144,145,146,148],{"name":138,"role":25,"phone":139,"phoneExt":10,"email":140},"Viktor Gurevich, MD, DMSc","+78125599759","vktrgurevich@gmail.com",{"name":142,"role":25,"phone":139,"phoneExt":10,"email":143},"Soreya Urazgildeeva, MD, DMSc","docsau64@yandex.ru",{"name":138,"role":21,"phone":10,"phoneExt":10,"email":10},{"name":142,"role":56,"phone":10,"phoneExt":10,"email":10},{"name":147,"role":56,"phone":10,"phoneExt":10,"email":10},"Alexey Tregubov, MD, PhD",{"name":149,"role":56,"phone":10,"phoneExt":10,"email":10},"Maria Muzalevskaya, MD, PhD",{"facility":151,"status":34,"city":152,"state":10,"zip":153,"country":37,"countryCode":38,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Samara State Medical University","Samara","443099",{"type":40,"coordinates":155},[156,157],50.13553,53.20767,{"lat":157,"lon":156},[160,164,168,170,171],{"name":161,"role":25,"phone":162,"phoneExt":10,"email":163},"Mikhail Kachkovsky, MD, PhD","+79171187181","kma10@yandex.ru",{"name":165,"role":25,"phone":166,"phoneExt":10,"email":167},"Olesya Rubanenko, MD, PhD","+79371887780","olesya.rubanenko@gmail.com",{"name":169,"role":21,"phone":10,"phoneExt":10,"email":10},"Mikhail Kachkovsky, MD, DMSc",{"name":165,"role":56,"phone":10,"phoneExt":10,"email":10},{"name":172,"role":21,"phone":10,"phoneExt":10,"email":10},"Dmitry Duplyakov, MD, DMSc",{"type":21,"investigatorFullName":174,"investigatorTitle":175,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Marat Vladislavovich Ezhov (MV Ezhov, MD, PhD, DMSc)","Leading Researcher, MD, DMSc",[177,180,182],{"name":178,"class":179},"Pfizer","INDUSTRY",{"name":181,"class":179},"Amgen",{"name":183,"class":179},"AstraZeneca","100225171","russian-familial-hypercholesterolemia-registry-100225171",false,"NCT02208869","Russian Familial Hypercholesterolemia Registry","Prospective Russian Study Evaluating the Extent of Underdiagnosed and Undertreated of Familial Hypercholesterolaemia in the Population","RuFH","Inclusion Criteria:\n\n* Total cholesterol ≥7.5 mmol\u002FL or LDL-C ≥4.9 mmol\u002FL (pretreatment levels)\n* Familial hypercholesterolemia defined as: a. Mutation in the LDL receptor and\u002For the ApoB gene and\u002For the PCSK9 gene; or b. clinical diagnosis of heterozygous FH (HeFH) according to the Dutch Lipid Network Criteria or Simon Broom Criteria\n* Patients with genetic mutation of FH\n\nExclusion Criteria:\n\n* uncontrolled primary hypothyroidism (thyroid stimulating hormone (TSH) \\>1.5 x upper limit of normal (ULN)),\n* nephrotic syndrome and\u002For renal dysfunction (scrum creatinine \\>2.0 mg\u002FdL or 160mmol\u002Fl, creatinine clearance \\\u003C15 ml\u002Fmin) at screening.\n* uncontrolled diabetes mellitus (Glycated hemoglobin \\>8.5%)","ALL","7 Years","80 Years",{"count":196,"type":197},1000,"ESTIMATED","10 Years","OBSERVATIONAL","True prevalence of FH in the Russian Federation is unknown which leads to low percentage of diagnosed and treated cases. Research is needed to determine the prevalence of FH, specific diagnostic algorithms and optimal treatment strategies. The main aim of the present study is to evaluate the extent to which FH is underdiagnosed and undertreated in the Russian Federation for reduction of cardiovascular risk related to atherosclerosis in the country.\n\nAs a first step, total cholesterol (TC) and low-density lipoprotein (LDL-C) levels will be determined in a random sample from Moscow population (n=18000). It is expected that TC ≥ 7.5 mmol\u002FL will be detected in 10% of cohort. During 2014, approximately 500 patients will pass through non-invasive clinical examination at the Russian Cardiology Research and Production Center, including patient demographics, past medical history, family history of hypercholesterolemia, physical findings, current lipid-lowering therapies, blood tests, genetic analysis, echocardiography, carotid duplex ultrasound and exercise SPECT imaging in selected cases. On the basis of the Moscow Program four major Federal Medical Centers will be involved, and FH Registry will be created as a national, multi-center initiative to screen FH patients, control their diagnosis and management, and track clinical-reported outcomes over time.\n\nEstablishment of National Guidelines for the diagnosis and treatment of FH on the basis of these data and implementation those into clinical practice in different regions of Russia will allow improving patient care. As an expected outcome, this program will raise awareness and increase appropriate assessment and treatment of FH patients in Russia, leading to a timely detection of the disease and therapy initiation.",[202],"Familial Hypercholesterolemia",[204,205,206,207,208,209,210],"familial hypercholesterolemia","cholesterol","prevention","registry","atherosclerosis","treatment","prevalence","2022-11-01",{"date":213,"type":214},"2022-11-02","ACTUAL",{"date":216,"type":10},"2014-01",{"date":218,"type":197},"2026-12-31",{"name":5,"class":6},5]